Hematological Malignancies

Radioimmunotherapy consolidation FIT Study

Start of study

90 Y-ibritumomab (n = 207) Rituximab 250 mg/m 2 IV on day −7 and day 0 + 90 Y-ibritumomab 14.8 MBq/kg (0.4 mCi/kg) [max 1184 MBq (32 mCi)] on day 0 CONSOLIDATION No further treatment (n = 202) CONTROL

R A N D O M I Z A T I O N

First-line therapy with chlorambucil, CVP, CHOP, CHOP-like, fludarabine combination, or rituximab combination INDUCTION Patients with previously untreated FL

6-12 weeks after last dose of induction

CR/CRu or PR

NR PD

Not Eligible

Morschhauser et al. J Clin Oncol . 2008;26:5156-5164